BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1699281)

  • 1. Phase I clinical trials with fludarabine phosphate.
    Von Hoff DD
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):33-8. PubMed ID: 1699281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive phase I and II clinical investigation of fludarabine phosphate.
    Grever M; Leiby J; Kraut E; Metz E; Neidhart J; Balcerzak S; Malspeis L
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):39-48. PubMed ID: 1699282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia.
    Keating MJ
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):49-62. PubMed ID: 1699283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma].
    Arima N; Mizoguchi H; Shirakawa S; Tomonaga M; Takatsuki K; Ohno R
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):619-29. PubMed ID: 10234292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients.
    Avramis VI; Champagne J; Sato J; Krailo M; Ettinger LJ; Poplack DG; Finkelstein J; Reaman G; Hammond GD; Holcenberg JS
    Cancer Res; 1990 Nov; 50(22):7226-31. PubMed ID: 1699658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
    Chun HG; Leyland-Jones B; Cheson BD
    J Clin Oncol; 1991 Jan; 9(1):175-88. PubMed ID: 1702143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine phosphate therapy of non-Hodgkin's lymphoma.
    Hochster H; Cassileth P
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):63-5. PubMed ID: 1699284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Issues for the future development of fludarabine phosphate.
    Cheson BD
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):71-8. PubMed ID: 1699286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.
    Binet JL
    Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):5-7. PubMed ID: 7685518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine phosphate therapy in other lymphoid malignancies.
    Kantarjian HM; Redman JR; Keating MJ
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):66-70. PubMed ID: 1699285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
    Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM
    J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.
    Rodriguez G
    Invest New Drugs; 1994; 12(2):75-92. PubMed ID: 7532163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
    Malspeis L; Grever MR; Staubus AE; Young D
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced head and neck cancer.
    Mittelman A; Savona S; Puccio C; Chun H; Ahmed T; Feldman E; Sullivan P; Arnold P; Arlin Z
    Invest New Drugs; 1990; 8 Suppl 1():S65-7. PubMed ID: 1696246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study.
    Spriggs DR; Stopa E; Mayer RJ; Schoene W; Kufe DW
    Cancer Res; 1986 Nov; 46(11):5953-8. PubMed ID: 2428488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule.
    Leiby JM; Grever MR; Staubus AE; Neidhart JA; Malspeis L
    J Natl Cancer Inst; 1988 May; 80(6):447-9. PubMed ID: 2452888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma.
    Ajani JA; Abbruzzese JL; Faintuch JS; Blackburn R; Levin B; Boman BM
    Invest New Drugs; 1988 Apr; 6(1):47-50. PubMed ID: 2457566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase II clinical study of SH L 573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia].
    Miyawaki S; Imamura M; Kobayashi S; Ohnishi K; Hodohara K; Mizoguchi H; Tomonaga M; Tango T; Ohno R
    Rinsho Ketsueki; 1999 Dec; 40(12):1236-44. PubMed ID: 10658476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New initiatives with fludarabine monophosphate in hematologic malignancies.
    Keating MJ; O'Brien S; Robertson LE; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Yang LY; Gandhi V
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):13-20. PubMed ID: 7694371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.
    Redman JR; Cabanillas F; Velasquez WS; McLaughlin P; Hagemeister FB; Swan F; Rodriguez MA; Plunkett WK; Keating MJ
    J Clin Oncol; 1992 May; 10(5):790-4. PubMed ID: 1373760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.